DATE CHANGE - October 6-9, 2022 - IWWM-12 Madrid, Spain
Dear Colleagues:
I am writing to you with great sorrow as we watch the coronavirus epidemic continue to impact lives across the globe. Over 500,000 of our fellow human beings have lost their lives to COVID-19, as both the death toll and number of coronavirus cases continues to grow. Here in the United States, the coronavirus cases have greatly increased with much strain on the medical system for many of our states. In addition, there have been many travel restrictions imposed for travel to/from the United States, and many other countries around the globe in response to the COVID-19 pandemic. Our recognition at this time is that it will not be possible to hold the IWWM-11 this year given the large safety concerns and travel restrictions.
Our initial intent was to move the workshop planned for this October in Madrid to 2022. We have succeeded in making this adjustment and have re-booked the WM workshop for the Westin Madrid for October 6-9, 2022. Our website has been adjusted to reflect this postponement. Our local chairs, Professors Ramon Garcia-Sanz and Jesus San Miguel have been very supportive of this adjustment, and we look forward to working with them on the program and being in Madrid as IWWM-12 in 2022.
We are also giving consideration at this time for a smaller WM workshop (IWWM-11) to be held next summer in Boston. This workshop would permit a smaller group of 40 persons to safely attend to discuss emerging data for WM and help in the development of WM treatment guidelines. While we thought this might have been possible for this Fall, the new realities of the COVID-19 crisis, and the feedback from many of our scientific advisors favored a live, but smaller meeting next year.
We will inform you of the details of the revised workshops once they become available. We thank you for all hard work and efforts on behalf of WM patients.
Steve Treon MD, PhD
Chair
WM Workshop Organizing Committee
Read more: DATE CHANGE - October 6-9, 2022 - IWWM-12 Madrid, Spain
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England
Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report. For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.
IWMF Virtual Educational Forum August 27-28, 2020
Join us at the 2020 IWMF Virtual Educational Forum - a unique opportunity to come together and learn from medical experts and WM community members around the world – all from the comfort of your own home! Experience our 2020 Vision: A World Without WM.
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for the treatment of Waldenström macroglobulinemia (WM).
The IWMF announces $800,000 in new research funding
The IWMF Board of Trustees has approved $800,000 in new research support for two research projects from the IWMF-LLS (Leukemia & Lymphoma Society) Strategic Research Roadmap initiative.
Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!
After undergoing eighteen months of chemotherapy ending in 2014, which resulted in much success and years of being well managed and free of infusions, my WM flared up again, significantly, in 2019. This required me to go back into treatment.
WM and COVID-19: WMUK Webinar Recordings
On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).
Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...
COVID-19 & Hematologic Malignancies: Patient Experience Update
We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.
Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.